KYMR Stock Analysis: Kymera Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.848m USD | 12M Return: 188.2% | US5015751044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 59.9M
Qual. Beats: 0
Rev. Trend: -19.3%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs that selectively degrade disease-causing proteins by harnessing the bodys natural protein degradation system, an approach referred to as targeted protein degradation. Its pipeline includes KT-621, an oral STAT6 degrader in Phase 2b trials for immune-mediated conditions including atopic dermatitis, asthma, and COPD; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases; the IRAK4 program (KT-485/SAR447971) in Phase II for immunology and inflammation indications; and a CDK2 program with potential applications in oncology, including breast cancer. As a clinical-stage biotech, Kymera has no approved products on the market and depends on capital markets and partnerships to fund development. The company has a strategic alliance with Sanofi S.A. for IRAK4-directed candidates outside the oncology and immuno-oncology fields, a typical structure in which large pharmaceutical companies license or co-develop assets originated by smaller biotechs. Kymera was incorporated in 2015, is headquartered in Watertown, Massachusetts, and trades on NASDAQ as a mid-cap biotechnology stock following its 2020 IPO.
- KT-621 STAT6 degrader Phase 2b atopic dermatitis results
- Sanofi IRAK4 alliance milestone payments and royalties
- Cash burn and dilution risk from pipeline expansion
| Net Income: -299.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 7.90 > 1.0 |
| NWC/Revenue: 630.8% < 20% (prev 1.43k%; Δ -802.4% < -1%) |
| CFO/TA -0.14 > 3% & CFO -236.8m > Net Income -299.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (98.2m) vs 12m ago 22.04% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 7.56% > 50% (prev 3.95%; Δ 3.61% > 0%) |
| Interest Coverage Ratio: -1.13k > 6 (EBIT TTM -350.2m / Interest Expense TTM 309k) |
| A: 0.40 (Total Current Assets 737.3m - Total Current Liabilities 75.0m) / Total Assets 1.65b |
| B: -0.73 (Retained Earnings -1.20b / Total Assets 1.65b) |
| C: -0.25 (EBIT TTM -350.2m / Avg Total Assets 1.39b) |
| D: 10.79 (Book Value of Equity 1.51b / Total Liabilities 139.9m) |
| Altman-Z'' = 9.91 = AAA |
| DSRI: 0.21 (Receivables 20.0m/40.0m, Revenue 105.0m/44.7m) |
| GMI: 0.80 (GM 81.87% / 102.0%) |
| AQI: 1.85 (AQ_t 0.50 / AQ_t-1 0.27) |
| SGI: 2.35 (Revenue 105.0m / 44.7m) |
| TATA: -0.04 (NI -299.6m - CFO -236.8m) / TA 1.65b) |
| Beneish M = -2.39 (Cap -4..+1) = BBB |
As of August 11, 2026, the stock is trading at USD 108.58 with a total of 396,410 shares traded. Over the past week, the price has changed by +8.24%, over one month by -9.02%, over three months by +29.11% and over the past year by +188.16%.
Current recommended Stop Loss: 98.50 (which is 9.3% or 2 ATR below the current price).
Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.
- StrongBuy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 127.2 | 17.1% |
P/S = 84.2672
P/B = 5.5168
Revenue TTM = 105.0m USD
EBIT TTM = -350.2m USD
EBITDA TTM = -341.9m USD
Long Term Debt = 64.9m USD (estimated: total debt 82.2m - short term 17.4m)
Short Term Debt = 17.4m USD (from shortTermDebt, last quarter)
Debt = 82.2m USD (from shortLongTermDebtTotal, last quarter) (leases 80.5m already included)
Net Debt = -608.8m USD (calculated: Debt 82.2m - CCE 691.0m)
Enterprise Value = 8.24b USD (8.85b + Debt 82.2m - CCE 691.0m)
Interest Coverage Ratio = -1.13k (Ebit TTM -350.2m / Interest Expense TTM 309k)
EV/FCF = -34.63x (Enterprise Value 8.24b / FCF TTM -238.0m)
FCF Yield = -2.89% (FCF TTM -238.0m / Enterprise Value 8.24b)
FCF Margin = -226.6% (FCF TTM -238.0m / Revenue TTM 105.0m)
Net Margin = -285.4% (Net Income TTM -299.6m / Revenue TTM 105.0m)
Gross Margin = unknown ((Revenue TTM 105.0m - Cost of Revenue TTM -2.08m) / Revenue TTM)
Tobins Q-Ratio = 5.01 (Enterprise Value 8.24b / Total Assets 1.65b)
Interest Expense / Debt = 0.38% (Interest Expense 309k / Debt 82.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -276.6m (EBIT -350.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.83 (Total Current Assets 737.3m / Total Current Liabilities 75.0m)
Debt / Equity = 0.05 (Debt 82.2m / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 1.78 (negative EBITDA) (Net Debt -608.8m / EBITDA -341.9m)
Debt / FCF = 2.56 (negative FCF - burning cash) (Net Debt -608.8m / FCF TTM -238.0m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.58% (Net Income -299.6m / Total Assets 1.65b)
RoE = -21.50% (Net Income TTM -299.6m / Total Stockholder Equity 1.39b)
RoCE = -24.01% (EBIT -350.2m / Capital Employed (Equity 1.39b + L.T.Debt 64.9m))
RoIC = -17.48% (negative operating profit) (NOPAT -276.6m / Invested Capital 1.58b)
WACC = 10.68% (E(8.85b)/V(8.93b) * Re(10.78%) + D(82.2m)/V(8.93b) * Rd(0.38%) * (1-Tc(0.21)))
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.86 | Cagr: 15.66%
[DCF] Fair Price = unknown (Cash Flow -238.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: -19.29 | Revenue CAGR: -7.01% | SUE: 1.98 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-1.03 | Chg30d=-0.15% | Revisions=-17% | Analysts=20
EPS current Year (2026-12-31): EPS=-3.51 | Chg30d=+0.11% | Revisions=-17% | GrowthEPS=+4.8% | GrowthRev=+117.8%
EPS next Year (2027-12-31): EPS=-4.36 | Chg30d=-0.23% | Revisions=-17% | GrowthEPS=-24.1% | GrowthRev=-51.9%
[Analyst] Revisions Ratio: -25% (up=3, down=6)